|
| 37980111 | Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion. | | 2024 |
| 37354600 | Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. | EBioMedicine | 2023 |
| 37626477 | Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor. | | 2023 |
| 37769429 | Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab. | | 2023 |
| 37269641 | Obesity, gut microbiota, and multiple sclerosis: Unraveling the connection. | | 2023 |
| 36889543 | Schwann Cell Remyelination in the Multiple Sclerosis Central Nervous System. | | 2023 |
| 36634138 | Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. | Proc Natl Acad Sci U S A | 2023 |
| 37004272 | Quantitative MRI identifies lesional and non-lesional abnormalities in MOGAD. | | 2023 |
| 37184849 | Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis? | | 2023 |
| 37119507 | Brain age predicts disability accumulation in multiple sclerosis. | | 2023 |
| 37364375 | Targeting miR-223 enhances myeloid-derived suppressor cell suppressive activities in multiple sclerosis patients. | | 2023 |
| 37356256 | Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. | | 2023 |
| 35196933 | Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS. | Multiple Sclerosis Journal | 2022 |
| 36178006 | Evaluating brain damage in multiple sclerosis with simultaneous multi-angular-relaxometry of tissue. | Annals of Clinical and Translational Neurology | 2022 |
| 35841895 | Further support for rituximab in relapsing multiple sclerosis. | Lancet Neurology, The | 2022 |
| 35839562 | COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes. | Mult Scler Relat Disord | 2022 |
| 36031693 | The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. | Mult Scler Relat Disord | 2022 |
| 35503396 | Correction to: COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. | Neurology and Therapy | 2022 |
| 35747540 | Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and Recommendations. | Neurology: Clinical Practice | 2022 |
| 35432382 | Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. | Frontiers in Immunology | 2022 |
| 35370433 | Stronger Microstructural Damage Revealed in Multiple Sclerosis Lesions With Central Vein Sign by Quantitative Gradient Echo MRI. | | 2022 |
| 35931008 | MINI-review of Epstein-Barr virus involvement in multiple sclerosis etiology and pathogenesis. | Journal of Neuroimmunology | 2022 |
| 33870786 | Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica. | Multiple Sclerosis Journal | 2022 |
| 35266417 | Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. | Multiple Sclerosis Journal | 2022 |
| 34850641 | Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal. | Multiple Sclerosis Journal | 2022 |
| 35229668 | Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5â¿¿years. | Multiple Sclerosis Journal | 2022 |
| 35094961 | Alterations of host-gut microbiome interactions in multiple sclerosis. | eBioMedicine | 2022 |
| 35284994 | COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. | Neurology and Therapy | 2022 |
| 34429342 | COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry. | Neurol Neuroimmunol Neuroinflamm | 2021 |
| 34166868 | Diffusion basis spectrum imaging measures anti-inflammatory and neuroprotective effects of fingolimod on murine optic neuritis. | NeuroImage: Clinical | 2021 |
| 33739362 | Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis. | JAMA Neurol | 2021 |
| 33785592 | CD11cCD88CD317 myeloid cells are critical mediators of persistent CNS autoimmunity. | Proceedings of the National Academy of Sciences of the United States of America | 2021 |
| 33943045 | Quantitative signal properties from standardized MRIs correlate with multiple sclerosis disability. | Annals of Clinical and Translational Neurology | 2021 |
| 33874812 | MS can be considered a primary progressive disease in all cases, but some patients have superimposed relapses - No. | Multiple Sclerosis Journal | 2021 |
| 33416892 | Effects of dietary restriction on neuroinflammation in neurodegenerative diseases. | Journal of Experimental Medicine | 2021 |
| 34516079 | and Investigation of S1PR1 Expression in the Central Nervous System Using [H]CS1P1 and [C]CS1P1. | ACS Chemical Neuroscience | 2021 |
| 34455391 | Alterations of the gut mycobiome in patients with MS. | eBioMedicine | 2021 |
| 31237799 | T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients. | Multiple Sclerosis Journal | 2020 |
| 31965889 | Can CSF biomarkers predict future MS disease activity and severity? | Multiple Sclerosis Journal | 2020 |
| 32371549 | Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammation. | Neurology: Neuroimmunology and NeuroInflammation | 2020 |
| 32367692 | In vivo evolution of biopsy-proven inflammatory demyelination quantified by R2t* mapping. | Annals of Clinical and Translational Neurology | 2020 |
| 32304291 | Deep learning with diffusion basis spectrum imaging for classification of multiple sclerosis lesions. | Annals of Clinical and Translational Neurology | 2020 |
| 31871296 | Diffusion basis spectrum imaging provides insights into MS pathology. | Neurology: Neuroimmunology and NeuroInflammation | 2020 |
| 31865272 | Clinical instrument to retrospectively capture levels of EDSS. | Multiple Sclerosis and Related Disorders | 2020 |
| 33551958 | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis. | Frontiers in Neurology | 2020 |
| 33551721 | Diffusion Basis Spectrum Imaging Detects Axonal Loss After Transient Dexamethasone Treatment in Optic Neuritis Mice. | Frontiers in Neuroscience | 2020 |
| 32769063 | Effects of MS disease-modifying therapies on responses to vaccinations: A review. | Multiple Sclerosis and Related Disorders | 2020 |
| 32757523 | Ofatumumab versus Teriflunomide in Multiple Sclerosis. | N Engl J Med | 2020 |
| 32702642 | Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica. | Multiple Sclerosis and Related Disorders | 2020 |
| 30834138 | The association between handedness and clinicodemographic characteristics in people with multiple sclerosis: a brief report. | Multiple Sclerosis Journal - Experimental, Translational and Clinical | 2019 |